Silo Pharma (SILO) surged over 85% pre-market after the European Patent Office granted a patent for its novel PTSD prevention therapy. Licensed from Columbia University, the drug targets stress resilience using 5-HT4 receptor agonists. CEO Eric noted the patent strengthens Silo's position in the massive, underserved mental health market by preventing stress-induced fear and depressive behaviours.